PMID- 33770500
OWN - NLM
STAT- MEDLINE
DCOM- 20220302
LR  - 20231101
IS  - 2213-6711 (Electronic)
IS  - 2213-6711 (Linking)
VI  - 16
IP  - 4
DP  - 2021 Apr 13
TI  - Low Immunogenicity and Immunosuppressive Properties of Human ESC- and 
      iPSC-Derived Retinas.
PG  - 851-867
LID - S2213-6711(21)00130-2 [pii]
LID - 10.1016/j.stemcr.2021.02.021 [doi]
AB  - ESC- and iPSC-derived retinal transplantation is a promising therapeutic approach 
      for disease with end-stage retinal degeneration, such as retinitis pigmentosa and 
      age-related macular degeneration. We previously showed medium- to long-term 
      survival, maturation, and light response of transplanted human ESC- and 
      iPSC-retina in mouse, rat, and monkey models of end-stage retinal degeneration. 
      Because the use of patient hiPSC-derived retina with a disease-causing gene 
      mutation is not appropriate for therapeutic use, allogeneic transplantation using 
      retinal tissue/cells differentiated from a stocked hESC and iPSC line would be 
      most practical. Here, we characterize the immunological properties of hESC- and 
      iPSC-retina and present their three major advantages: (1) hESC- and iPSC-retina 
      expressed low levels of human leukocyte antigen (HLA) class I and little HLA 
      class II in vitro, (2) hESC- and iPSC-retina greatly suppressed immune activation 
      of lymphocytes in co-culture, and (3) hESC- and iPSC-retina suppressed activated 
      immune cells partially via transforming growth factor beta signaling. These results 
      support the use of allogeneic hESC- and iPSC-retina in future clinical 
      application.
CI  - Copyright (c) 2021 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - Yamasaki, Suguru
AU  - Yamasaki S
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan; Regenerative & Cellular Medicine Kobe Center, 
      Sumitomo Dainippon Pharma Co., Ltd., Kobe 650-0047, Japan.
FAU - Sugita, Sunao
AU  - Sugita S
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan. Electronic address: sunao.sugita@riken.jp.
FAU - Horiuchi, Matsuri
AU  - Horiuchi M
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan; Regenerative & Cellular Medicine Kobe Center, 
      Sumitomo Dainippon Pharma Co., Ltd., Kobe 650-0047, Japan.
FAU - Masuda, Tomohiro
AU  - Masuda T
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan.
FAU - Fujii, Shota
AU  - Fujii S
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan.
FAU - Makabe, Kenichi
AU  - Makabe K
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan.
FAU - Kawasaki, Akihiro
AU  - Kawasaki A
AD  - Laboratory for Brain Connectomics Imaging, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan.
FAU - Hayashi, Takuya
AU  - Hayashi T
AD  - Laboratory for Brain Connectomics Imaging, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan.
FAU - Kuwahara, Atsushi
AU  - Kuwahara A
AD  - Regenerative & Cellular Medicine Kobe Center, Sumitomo Dainippon Pharma Co., 
      Ltd., Kobe 650-0047, Japan.
FAU - Kishino, Akiyoshi
AU  - Kishino A
AD  - Regenerative & Cellular Medicine Kobe Center, Sumitomo Dainippon Pharma Co., 
      Ltd., Kobe 650-0047, Japan.
FAU - Kimura, Toru
AU  - Kimura T
AD  - Regenerative & Cellular Medicine Kobe Center, Sumitomo Dainippon Pharma Co., 
      Ltd., Kobe 650-0047, Japan.
FAU - Takahashi, Masayo
AU  - Takahashi M
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan.
FAU - Mandai, Michiko
AU  - Mandai M
AD  - Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics 
      Research, Kobe 650-0047, Japan; RIKEN Program for Drug Discovery and Medical 
      Technology Platforms (DMP), RIKEN Cluster for Science, Technology and Innovation 
      Hub, Saitama 351-0198, Japan. Electronic address: michiko.mandai@riken.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210325
PL  - United States
TA  - Stem Cell Reports
JT  - Stem cell reports
JID - 101611300
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Transforming Growth Factor beta)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - *Cell Differentiation/drug effects
MH  - Histocompatibility Antigens Class I/metabolism
MH  - Human Embryonic Stem Cells/*cytology/drug effects/transplantation
MH  - Humans
MH  - Immunomodulation/drug effects
MH  - *Immunosuppression Therapy
MH  - Induced Pluripotent Stem Cells/*cytology/drug effects/metabolism
MH  - Interferon-gamma/pharmacology
MH  - Leukocytes, Mononuclear/drug effects/metabolism
MH  - Primates
MH  - Recombinant Proteins/pharmacology
MH  - Retina/*immunology
MH  - Retinal Pigment Epithelium/cytology
MH  - Transforming Growth Factor beta/metabolism
PMC - PMC8072071
OTO - NOTNLM
OT  - ESCs
OT  - iPSCs
OT  - inflammation
OT  - retina
OT  - suppression
EDAT- 2021/03/27 06:00
MHDA- 2022/03/03 06:00
PMCR- 2021/03/25
CRDT- 2021/03/26 20:09
PHST- 2020/07/30 00:00 [received]
PHST- 2021/02/25 00:00 [revised]
PHST- 2021/02/27 00:00 [accepted]
PHST- 2021/03/27 06:00 [pubmed]
PHST- 2022/03/03 06:00 [medline]
PHST- 2021/03/26 20:09 [entrez]
PHST- 2021/03/25 00:00 [pmc-release]
AID - S2213-6711(21)00130-2 [pii]
AID - 10.1016/j.stemcr.2021.02.021 [doi]
PST - ppublish
SO  - Stem Cell Reports. 2021 Apr 13;16(4):851-867. doi: 10.1016/j.stemcr.2021.02.021. 
      Epub 2021 Mar 25.